<DOC>
	<DOCNO>NCT00021359</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy dexamethasone may effective treatment multiple myeloma . PURPOSE : Phase II trial study effectiveness combine isotretinoin dexamethasone treat patient multiple myeloma .</brief_summary>
	<brief_title>Isotretinoin Plus Dexamethasone Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate duration response patient multiple myeloma treat dexamethasone isotretinoin . II . Determine toxicity regimen patient . III . Correlate change serum interleukin ( IL ) -6 , IL-6R , C-reactive IL-6R expression plasma cell bone marrow response patient treat regimen . OUTLINE : Patients receive oral dexamethasone day 1-4 , 9-12 , 17-20 oral isotretinoin daily . Treatment repeat every 5 week least 2 course absence disease progression , insufficient response , unacceptable toxicity . Patients achieve adequate response continue treatment 2 course achieve plateau monoclonal protein , minimum 6 course total . PROJECTED ACCRUAL : A total 18-36 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma Elevated monoclonal protein serum and/or urine PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3* Platelet count least 75,000/mm3* *Unless secondary multiple myeloma involvement bone marrow Hepatic : Bilirubin le 1.5 mg/dL Transaminase le 2 time normal Renal : Creatinine le 2.0 mg/dL No overt renal insufficiency Cardiovascular : No congestive heart failure No myocardial infarction within past 6 month No significant arrhythmia poorly control hypertension Pulmonary : No severe pulmonary disease Other : Triglycerides normal No severe medical illness No active peptic ulcer disease No brittle insulindependent diabetes No severe depression psychiatric illness No active infection No history severe ethanol drug abuse Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior palliative radiotherapy allow Surgery : At least 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>